Partnering

Building a leading, global mRNA therapeutics company

0

rare disease programs

0

issued patents

0

pending patent applications

Our Strategy

Translate Bio’s MRT platform has the potential to change the lives of people living with debilitating genetic diseases.

Our goal is to continue building a leading, global mRNA therapeutics company that capitalizes on our extensive experience with proprietary mRNA product development, delivery, manufacturing and process development. We are developing our first-in-class MRT product candidates in CF and OTC deficiency that have the potential to transform these debilitating and life-threatening illnesses into manageable chronic conditions with an improved quality of life.

We plan to leverage the broad applicability of our MRT platform by developing additional MRT product candidates for our own pipeline. Specifically, we intend to:

  • Maintain our initial focus on genetic diseases with high unmet medical need in the lungs and liver to utilize our platform to rapidly develop new product candidates targeting these tissues.
  • Broaden our focus to develop product candidates that address diseases with high unmet medical need, including CNS disorders, ocular diseases and blood disorders.

Our Partners

In June 2018, we announced a collaboration and exclusive licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to five infectious disease pathogens which will bring together Sanofi Pasteur’s leadership in vaccines and our mRNA research and development expertise.

 

Let’s Talk

We’re interested in partnering with other dedicated experts to transform mRNA science into meaningful therapies